Toleranzia develops drugs that utilize the immune system’s own intrinsic power to treat autoimmune orphan diseases. The drugs that target the cause of the disease can cure or greatly alleviate the disease and not only reduce the symptoms which currently available treatments do.
Impact: A treatment of the autoimmune neuromuscular disease myasthenia gravis, which has a major unmet medical need.
CEO: Charlotte Fribert
GUV Contact: Anders Waas
Location: Sweden, Gothenburg
Employees: 11-50
Total raised: $4.85M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | GU Venture... | guventures... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.09.2021 | - | $4.85M | - |
Mentions in press and media 1
| Date | Title | Description | Source |
| 21.09.2021 | Toleranzia AB (publ): Receives approximately SEK 42 million ... | Toleranzia AB (publ) (”Toleranzia” or the ”Company”) today announces the outcome of the directed sha... | marketscre... |